Johnson & Johnson has received U.S. Food and Drug Administration approval for an accelerated monthly dosing regimen of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) combined with Lazcluze for patients with EGFR-mutated advanced non-small cell lung cancer. The new dosing schedule, which can begin as early as Week 1 of treatment, maintains clinical efficacy comparable to the previously approved bi-weekly administration protocol, potentially offering patients greater convenience and reduced treatment burden.
This regulatory decision represents a significant expansion of the subcutaneous formulation approved in December 2025, which already demonstrated reduced infusion times and lower rates of administration-related adverse events compared to earlier intravenous formulations. The monthly dosing option addresses a critical quality-of-life consideration for cancer patients, as more frequent clinic visits can impact overall treatment tolerability and patient compliance.
The approval underscores the evolving treatment landscape for advanced lung cancer, where therapeutic efficacy is increasingly paired with practical considerations around patient convenience and healthcare resource utilization. This development may position Rybrevant Faspro more competitively in the EGFR-mutated lung cancer market, where dosing frequency and administration burden remain important factors in treatment selection.